Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR-TRC-10001108Phase 4Completed
Phase 4, randomised, open-label trial of capecitabine in rectal cancer (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 3-year disease-free survival. Started Jan 2010; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR-TRC-10001108.